Greenyn Biotechnology Co

Greenyn Biotechnology Co Current Liabilities

The Current Liabilities of Greenyn Biotechnology Co (6846.TWO) as of Nov 2, 2026 is 74.53 M TWD. In the previous year, Current Liabilities was 143.40 M TWD — a change of -48.03% (lower).

Current Liabilities

74.53 MTWD

YoY

-48.03%

Last updated:

Current Liabilities of Greenyn Biotechnology Co is 2025 74.53 M TWD. Current Liabilities of Greenyn Biotechnology Co was 2024 143.40 M TWD. It decreases by -48.03% lower compared to the previous year.

The Greenyn Biotechnology Co Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2019
183.94 M TWD
Jan 1, 2020
212.61 M TWD
Jan 1, 2021
49.93 M TWD
Jan 1, 2022
58.16 M TWD
Jan 1, 2023
130.40 M TWD
Jan 1, 2024
143.40 M TWD
Jan 1, 2025
74.53 M TWD
The Greenyn Biotechnology Co Current Liabilities history
YEARCurrent LiabilitiesYoY
74.53 MTWD-48.03%
143.40 MTWD+9.97%
130.40 MTWD+124.23%
58.16 MTWD+16.47%
49.93 MTWD-76.51%
212.61 MTWD+15.59%
183.94 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Greenyn Biotechnology Co Stock analysis

What does Greenyn Biotechnology Co do? Greenyn Biotechnology Co., Ltd. generates revenue through the research, development, manufacture, and sales of health food raw materials across three business segments: health ingredients, health formulations, and other segments. Its main products include Antrodia cinnamomea mycelia, Bitter melon extract (Insumate), and 101 Phyto Fermented Drink, which are primarily sold in Taiwan and other Asian regions. The company focuses on supplying these health-focused products to customers within the Asian market, leveraging its product portfolio for regional demand. The firm's product lineup targets health-conscious consumers seeking natural health solutions, with Antrodia cinnamomea mycelia and Bitter melon extract (Insumate) serving as key offerings. 101 Phyto Fermented Drink represents another core product, emphasizing plant-based health benefits. These products are distributed through established channels in Taiwan and neighboring Asian markets, supporting the company's regional sales strategy. Greenyn Biotechnology's business model centers on developing and commercializing specialized health ingredients and formulations, with a strong emphasis on Asian market penetration. The company's revenue streams are derived from the direct sale of its proprietary health food raw materials to customers in Taiwan and other Asian regions, without mentioning external partners or additional distribution channels beyond the specified markets. Greenyn Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Greenyn Biotechnology Co stock

Current Liabilities of Greenyn Biotechnology Co is 74.53 M TWD in 2025.

Current Liabilities of Greenyn Biotechnology Co changed from 143.40 M TWD to 74.53 M TWD, representing a -48.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Greenyn Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Greenyn Biotechnology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Greenyn Biotechnology Co

All Key Metrics — Greenyn Biotechnology Co